Figure 4.
Brain penetration of SPH3643 in intracranial glioblastoma xenografts. Mean plasma (A) and brain (B) pharmacokinetic profiles and the brain : plasma ratios (C) of SPH3643, LY2835219, and palbociclib after oral treatment for 1.5‐24 h. *P < .05, **P < .01